1Matetzky S,Shenkman B,Guetta V,et al.Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction[J].Circulation,2004,109(25):3171-3175.
2Iba MM,Fung J,Pak YW,et al.Dose-dependent up-regulation of rat pulmonary,renal,and hepatic cytochrome P-450 (CYP) 1A expression by nicotine feeding[J].Drug Metab Dispos,1999,27(9):977-982.
3CAPRIE Steering Committee.A randomized,blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE)[J].Lancet,1996,348(9038):1329-1339.
4CURE Study Investigators.The Clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme ; rationale,design and baseline characteristics including a metaanalysis of the effects of thienopyridines in vascular disease[J].Eur Heart J,2000,21(24):2033-2041.
5Sabatine MS,Cannon CP,Gibson CM,et al.Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation[J].N Eng J Med,2005,352(12):1179-1189.
6Umesh NK,Steven EN.Is CURE a cure for acute coronary syndromes?statistical versus clinical significance[J].JACC,2002,40(2):218-219.
7Steinhubl SR,Berger PB,Mann III JT,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J].JAMA,2002,288(19):2411-2420.
8Harrington RA,Becker RC,Ezekowitz M,et al.Antithrombotic therapy for coronary artery disease:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 suppl):513S-548S.
9Bertrand ME,Rupprecht HJ,Urban P,et al.Double-Blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stent international cooperative study (CLASSICS)[J].Circulation,2000,102(6):624-629.
10Kandzari DE,Berger PB,Kastrati A,et al.Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization[J].J Am Coll Cardiol,2004,44(11):2133-2136.
二级参考文献20
1Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost,2000; 84:891 - 896.
2Jarvis Blair, Simpson Kerryn. Clopidogrel : A Review of its Use in the Prevention of Atherothrombosis. Drugs, 60(2) : 347-377.
3Kearney AS, Crawford LF, Mehta SC, et al. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxuacid forms of the HMG - CoA reductase inhibitor, CI - 981.Pharm Res, 1993; 10:1461 - 1465.
4Lea AP, McTavish D. Atorvastatin : a review of its pharmacology and therapeutic potential in the management of hyperlipidemias.Drugs, 1997;53:828 - 847.
5Thummel KE,Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol, 1998; 38: 389 - 430.
6Tannous M, Cheung R, Vignini A, et al. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.Thromb Haemost, 1999; 82 (5) : 1390 - 1394.
7Viigimaa M, Valkman R. Lipid - lowering and anti - aggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia. Atherosclerosis 1999 May 24; 144 Suppl.1:24.
8Hebert PR, Gaziano JM, Chan KS, et al.Cholesterol loweing with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA, 1997;278:1660 - 1661.
9Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardic events following successful first percutaneous coronary intervention: a randomized controlled trial .IAMA, 2002;287: 3215-3 222.
10Serebruany VL, Malinin AI, Kallahan KP, et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting.Atherosclerosis, 2001; 239:259 - 261.
